Creating a risk assessment tool for thunderstorm asthma (CARISTA)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

CARISTA will recruit adults with seasonal allergic rhinitis (hay fever) in South‑Eastern Australia and measure baseline lung function, sensitisation to ryegrass pollen, and blood inflammatory markers such as eosinophils. Participants will log symptoms and medication use through a secure customised platform across two consecutive spring pollen seasons. The study will record moderate or severe asthma exacerbations defined by emergency visits, oral steroid use, or escalation of preventive therapy. Collected clinical and biomarker data will be used to develop a risk model to identify people most likely to experience seasonal or thunderstorm asthma.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Consenting adults aged 18 to 70 years with seasonal allergic rhinitis

willing to undertake:

* Lung function testing
* Blood sample collection for risk factor identification, -Prospectively logging their symptoms and medications through the springtime season using the CARISTA symptom monitoring platform . -

Exclusion Criteria:

* Individuals unable to provide informed consent
* Individuals who do not suffer from symptoms of seasonal allergic rhinitis
* Individuals who do not consent to lung function testing and blood sample collection - Individuals with unstable asthma (FEV1 by spirometry less than 70% predicted), a recent exacerbation or change of asthma preventive medication use (within one month) would be excluded, although re-screening would be permitted after one month, time permitting.
* Individuals with severe asthma requiring the use of continuous oral corticosteroids or biological medication for severe asthma.
* The presence of any medical illness, such as cardiac disease, pre-existing illness or immunomodulatory therapy that, in the opinion of the Investigators, would compromise participant safety or the derivation of biomarkers during the study.

Where it's running

• Albury-Wodonga Health
  Albury, New South Wales, Australia Recruiting
• Eastern Health
  Box Hill, Victoria, Australia Recruiting
• Monash Health
  Clayton, Victoria, Australia Recruiting
• Austin Health
  Heidelberg, Victoria, Australia Recruiting
• The Alfred Hospital
  Melbourne, Victoria, Australia Recruiting
• The Royal Melbourne Hospital
  Parkville, Victoria, Australia Recruiting

Study contacts

• Principal investigator: Phillip Bardin, MD — Hudson Institute of Medical Research
• Study coordinator: Jo A Douglass, MD
• Email: jdouglass@unimelb.edu.au
• Phone: +6183444578

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mannan-Conjugated Allergoids for House Dust M mite Allergy

  A new treatment named EP-088_MM09 is being tested to see if it can reduce nasal and eye allergy symptoms (and possibly asthma) in people aged 12 to 65 who are allergic to house dust mites, compared with a placebo.

  Recruiting at 2 sites Phase 3 Inmunotek S.L. · Covilha, Castelo Branco District and 15 other locations · NCT07904195

• Mannan-conjugated Allergoids for House Dust Mite Allergy

  A new treatment called EP-088_MM09 is being tested to see if it can reduce allergy symptoms in people with house dust mite–related nasal allergy, with or without mild asthma.

  Recruiting at 4 sites Phase 3 Inmunotek S.L. · Coimbra and 15 other locations · NCT07904052

• Rupatifen Fumarate Capsules for Seasonal Allergic Rhinitis

  This Phase 3 trial tests Rupatifen Fumarate Capsules in adults with seasonal allergic rhinitis to see if they reduce symptoms compared with Rupatadine Fumarate and placebo.

  Recruiting at 18 sites Phase 3 Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · Baoding, Hebei and 17 other locations · NCT07711262

• Rademikibart IV for Acute Asthma and COPD Exacerbation

  This study tests a one-time IV dose of rademikibart to help people with acute asthma or COPD flare-ups who need urgent care.

  Recruiting at 2 sites Phase 2 Connect Biopharm LLC · Miami, Florida and 2 other locations · NCT07705737

• Explainable AI helps families manage obesity in kids and young adults with diabetes or asthma

  This study tests a family-centered digital program to help adolescents and young adults with overweight or obesity, including those with Type 1 diabetes or asthma, see if the program improves wellbeing and healthy habits over 3 months.

  Recruiting Adhera Health, Inc. · Seville · NCT07638345

• Post-Exacerbation Asthma Telecare

  This trial tests whether a structured remote pulmonology follow-up after an asthma flare‑up can reduce repeat exacerbations compared with usual care.

  Recruiting Tel-Aviv Sourasky Medical Center · Tel Aviv · NCT07629830

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.